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Abstract: Painful diabetic neuropathy (PDN) is one of the most common complications of dia-
betes mellitus. Recently it has become clear that nitric oxide (NO) and proinflammatory cytokines 
play an important role in the pathogenesis of PDN. We investigated whether the cytokine tumor 
necrosis factor alpha (TNF-α) and NO play a role in PDN pathogenesis by performing a cross-
sectional and a case–control study in 110 type 2 diabetic patients. Of 110 subjects, 59 patients 
suffered from PDN (cases) and the remaining were painless DN (controls).   Cross-sectionally, 
plasma TNF-α levels and immunoreactivity for inducible NO synthase (iNOS) and TNF-α were 
higher in patients with more severe pain on the visual analog scale. There were statistically 
significant differences between mild and severe pain for TNF-α levels, iNOS immunoreactivity, 
and TNF-α immunoreactivity. There were statistically significant differences between mild and 
severe pain for TNF-α levels (mean 15.24 pg/mL ± 5.42 vs 20.44 ± 10.34), iNOS immunore-
activity (9.76% ± 8.60% vs 15.48% ± 11.56%), and TNF-α immunoreactivity (13.0% ± 9.48% 
vs 20.44% ± 11.75%). The case–control study showed that TNF-α had an odds ratio of 5.053 
(P , 0.001), TNF-α immunoreactivity of 4.125 (P , 0.001), and iNOS immunoreactivity of 
3.546 (P = 0.002). DN patients with high TNF-α levels, and high iNOS and TNF-α expression 
in macrophages are at risk of suffering from pain. The higher the TNF-α level, and iNOS and 
TNF-α immunoreactivity, the more severe the pain. These findings could form the basis of 
further research into better management of PDN.
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Background
Uncontrolled diabetes can lead to acute and chronic complications, disability, and 
death. Diabetic neuropathy (DN) is a common complication of diabetes that can 
cause significant morbidity and mortality. It can be painful or painless. The reason 
for this difference in clinical presentation is as yet unknown.1 The prevalence of pain-
ful diabetic neuropathy (PDN) in a population-based sample is 26.4%.2 It can have a 
serious impact on quality of life, leading to severe depression and even suicide. The 
pathogenesis of PDN is complex and still poorly understood. In the past, research 
on neuropathic pain was focused on neurons and neurotransmitters. Recently it has 
become clear that nitric oxide (NO) and proinflammatory cytokines play an important 
role in the pathogenesis and maintenance of neuropathic pain. Neuroinflammation and 
neuroimmune activation occur following injury to peripheral nerves and nerve roots 
as well as in peripheral inflammatory models of persistent pain.3,4
The role of cytokines in the induction and maintenance of pain has been established 
in animal models, and clinical research has also provided evidence for the involvement Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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of cytokines in painful and painless neuropathies.5 Peripheral 
nerve injury induces activation of resident immune cells 
as well as recruitment of inflammatory cells to the site of 
lesion. There is increasing knowledge of the intracellular 
cascades that are activated in nociceptors by some mediators 
such as tumor necrosis factor alpha (TNF-α), interleukin 
(IL)-1β, IL-6, NO, prostaglandins (PG), nerve growth factor 
(NGF), and cyclo-oxygenase 2 (COX-2), which ultimately 
either activate or sensitize these neurons. Nerve injury also 
initiates Schwann cell de-differentiation and the release 
of several algesic mediators such as pro-inflammatory 
cytokines, NGF, prostaglandin E2 (PGE2), and ATP. This 
cocktail of mediators serves as a mechanism of enhanced 
inflammatory response in the injured nerve and contributes 
to neuropathic pain.6,7
TNF-α has been shown to be directly involved in the 
production of pain in several models of nerve injury. The 
effect of TNF-α on neurons seems to be mediated, directly 
and/or indirectly, by the phosphorylation of extracellular-
regulated kinase and p38 mitogen-activated protein kinase,8 
translocation of nuclear factor kappa B (NFκB) to the 
nucleus, and activation of COX-2-dependent prostanoid 
release.9 The phosphorylation of p38 mitogen-activated 
protein kinase may mediate mechanical allodynia via a 
modulation of tetrodotoxin-resistant Na channels.10 TNF-α 
also activates NFκB for initiation of NOS (NO synthase), 
and NO production whereas NO is a pain neurotransmitter.11 
Inhibition of serum TNF-α and NO levels with insulin and 
its combinations with resveratrol and curcumin contribute in 
attenuating DN pain, since TNF-α plays an important role 
in the development of DN.12
The role of NO in pathogenesis of PDN seems to be via 
upregulation of inducible NO synthase (iNOS) as a result of 
chronic inflammation. Lowenstein et al showed that there 
were reciprocal interactions between NO and PG, high levels 
of NO increased PDN, and iNOS inhibitor attenuated PDN.11 
With this background, the present study was designed to 
explore the plasma levels of TNF-α and iNOS and TNF-α 
expression in macrophages as risk factors for PDN.
Methods
subjects
One hundred and ten type 2 diabetic patients who fulfilled 
inclusion criteria were enrolled in this study (61 women and 
59 men, mean age 54.1, range 37–65 years). Patients were 
recruited consecutively at the outpatient Clinic of Neurol-
ogy and Internal Medicine Sanglah Hospital Denpasar, Bali 
from 1 October 2008 until 31 July 2009. The patients had 
a mean duration of diabetes of 5.30 years (2–10 years). 
Of 110 subjects, 59 patients suffered from PDN (cases) and 
the remaining 51 patients had painless DN (controls). The 
clinical characteristic of subjects and comparison of case and 
control group are given in Tables 1 and 2.
Inclusion criteria for the cross-sectional study were type 
2 diabetes patients, age 20–65 years, duration of diabetes 
2–10 years, and signed written informed consent. For the 
case–control study, the criteria were the same as for the 
cross-sectional study plus painless DN for control and PDN 
for case.
Exclusion criteria included: ongoing local and   systemic 
infection (documented with a blood cell count and erythrocyte 
sedimen rate), active ulcer in the leg, patients under   treatment 
with glyceryl trinitrate or sildenafil, herbal or synthetic 
medications containing antioxidant or anti-  inflammatory 
substances, and patients suffering from other types of neu-
ropathic pain. To minimize confounding   factors for blood 
cytokine levels, the study conditions were standardized by 
applying the following exclusion criteria: heavy physical 
activity in the last 3 days, food intake within 60 minutes 
before blood sampling, alcohol consumption up to 24 hours 
before the examination, and any current infectious disease 
or fever.
Procedure
The study was carried out in two steps. The first step was 
cross-sectional study and the second step was a case–
control study. In the cross-sectional study, type 2 diabetic 
patients who visited the outpatient Neurology and Internal 
Medicine Clinic Sanglah Hospital underwent anamnesis, 
Table 1 characteristics of diabetic neuropathy patients
Variable N Range Mean ± SD
Age (years) 110 37–65 54.11 ± 7.64
gender
  Women 61
  Men 49
Duration of DM (years) 110 2–10   5.30 ± 3.05
PDn
  Yes 59
  no 51
Fasting blood sugar (mg %) 110 65–363    167 ± 70
Blood sugar 2 hours pp (mg %) 110 102–588    255 ± 105
hbA1c (%) 110 3.30–18.60   9.69 ± 3.49
Plasma TnF-α (pg/mL) 110 5.40–56.64 15.06 ± 7.01
TnF-α expression (%) 110 0–40 12.43 ± 10.36
inOs expression (%) 110 0–38   9.22 ± 9.33
Abbreviations:  DM,  type  2  diabetes;  hbA1c,  glycosylated  hemoglobin;  inOs, 
inducible nitric oxide synthase; pp, post prandial; sD, standard deviation; TnF-α, 
tumor necrosis factor alpha.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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  neurological,   laboratory, and electromyoneurography 
(ENMG)   examinations. Anamnesis included: sensory, 
motor, and autonomic symptoms of DN. The neurologic 
examination included: sensory, motor, autonomic functions, 
and reflexes. The diagnosis of a DN was based on a typical 
history and thorough neurologic and ENMG examinations. 
Laboratory studies included: erythrocyte sedimentation 
rate, whole blood, blood sugar, glycosylated hemoglobin 
(HbA1C), urea, creatinine, and liver function test. A complete 
  electrophysiologic assessment with standard nerve conduc-
tion studies in motor and sensory nerves at upper and lower 
extremities was performed in all diabetic patients. Nerve 
conduction studies revealed low compound muscle action 
potentials and sensory nerve action potentials or low con-
duction velocities.
Patients who had DN and fulfilled inclusion criteria were 
recruited in the case–control study and were asked to assess 
their pain intensity on a visual analog scale (VAS), with 
0 representing no pain and 10 representing the worst pain 
imaginable. Patients were assigned to two groups according 
to their VAS: 1–5 mild pain and 6–10 severe pain. Patients 
were examined by blood tests for plasma TNF-α levels by 
ELISA and for iNOS and TNF-α expression in macrophages 
immunohistochemically.
Blood for TNF-α analysis was drawn in the morning, 
stored at 4°C, centrifuged at 1500 rpm for 10 minutes, and 
the plasma was stored at −20°C until assayed. The presence of 
TNF-α in plasma was detected by a commercially available 
ELISA Kit (R&D system, Wiesbaden, Germany).
Detection of TNF-α and iNOS expression in mac-
rophages  was  performed  immunohistochemically. 
  Approximately 3 mL blood was collected from DN patients. 
The blood was centrifuged at 1500 rpm for 10 minutes and 
the plasma   collected into small aliquots. Buffy coat layer 
at the interface was collected into a clean centrifuge tube. 
Red blood cells present in the buffy coat were lyzed using 
0.8% NH4Cl for 1 minute and leukocytes were pelleted by 
  centrifugation as above. Leukocytes were washed twice 
by repeated   centrifugation and a thin smear of leukocytes 
at a density of 1 million per 1 mL phosphate-buffered 
saline (PBS) was prepared on poly-L-lysine microscope 
slides. After air drying, the leukocytes were fixed with 
cold acetone for 20 minutes. The endogenous peroxidase 
of the leukocytes was then inactivated by 3% H2O2 in 
PBS for 30 minutes at room temperature. After blocking 
with 2% skim milk in PBS, monoclonal antibodies (Mab) 
against TNF-α (BIODESIGN International®, Saco, ME) 
and against iNOS (Santa Cruz Biotechnology, Inc, Santa 
Cruz, CA) was added into leukocytes smear on microscope 
slides. After three washes with PBS (pH. 7.4) and incuba-
tion for 1 hour at room temperature, the bound Mabs were 
detected by biotinylated goat anti-mouse IgG (BIODE-
SIGN International) and avidin-horse radish peroxidase 
(Sigma-Aldrich, St Louis, MO). The expression of TNF-α 
and iNOS was then visualized by adding diazinobenzidine 
substrates (Sigma-Aldrich; 50 mg/50 mL PBS containing 
0.07% H2O2). The mononuclear cells expressing iNOS and 
TNF-α were counted under 450× magnification by observa-
tion of 100 cells.
Data obtained from this study comprised descriptive 
analysis, Student’s t-test, bivariate correlation test, and cross 
tab (chi-square test and odds ratio). The data were analyzed 
using SPSS software, version 15, with significance set at 
P , 0.05.
Results
cross-sectional study
Of 110 subjects, 59 patients suffered from PDN which 
consisted of mild pain in 34 and severe pain in 25. Plasma 
TNF-α levels, and iNOS and TNF-α expression were higher 
in patients with more severe pain in the VAS (P , 0.05) as 
shown in Figure 1.
Table 2 comparison of clinical data of painful Dn (cases) and painless Dn (controls)
Characteristics Case mean ± SD Control mean ± SD  P
Age (years)   53.97 ± 8.26   54.27 ± 6.94 0.834
Duration of diabetes (years)   5.31 ± 3.13   5.29 ± 2.99 0.985
Fasting blood sugar (mg %) 168.96 ± 73.02 165.31 ± 69.14 0.789
Blood sugar 2 hours pp (mg %) 259.37 ± 109.51 251.96 ± 100.77 0.714
hbA1c (%)   10.40 ± 3.61   8.88 ± 3.18 0.023a
Plasma TnF-α (pg/mL)   17.44 ± 8.23   12.30 ± 3.76 ,0.001a
inOs expression (%)   12.18 ± 10.27   5.80 ± 6.41 ,0.001a
TnF-α expression (%)   16.15 ± 11.05   8.13 ± 7.56 ,0.001a
Note: aStatistically significant.
Abbreviations: Dn, diabetic neuropathy; hbA1c, glycosylated hemoglobin; inOs, inducible nitric oxide synthase; pp, post prandial; sD, standard deviation; TnF-α, tumor 
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between plasma TNF-α, and iNOS and TNF-α expression 
in macrophages as risk factors of PDN, a bivariate correla-
tion test was conducted. There were positive correlations 
between 3 risk factors above that statistically significant 
(P , 0.05).   Correlation between plasma TNF-α and iNOS 
expression was moderate (r = 0.351), correlation between 
plasma TNF-α and TNF-α expression was also moderate 
(r = 0.389), whereas correlation between TNF-α and iNOS 
expression was strong (r = 0.708).
Cross-sectionally the higher the plasma TNF-α levels, 
and the iNOS and TNF-α expression in macrophages, the 
more severe the pain. There were positive correlations 
between pain intensity and plasma TNF-α levels, and 
iNOS and TNF-α expression, and also moderate to strong 
  correlations between the three risk factors above.
case-control study
DN patients with high plasma TNF-α levels had a higher 
risk of getting PDN than those with low plasma TNF-α 
levels (odds ratio [OR] 5.053, 95% confidence interval [CI] 
2.241–11.392; P , 0.001).
DN patients with high TNF-α expression had a higher 
risk of getting PDN than those with low TNF-α expression 
(OR 4.125; 95% CI, 1.805–9.425; P , 0.001).
DN patients with high iNOS expression had a higher risk 
of getting PDN than those with low TNF-α expression (OR 
3.546; 95% CI, 1.613–7.795; P , 0.002).
High HbA1C levels did not increase the risk of getting 
PDN compared with low plasma HbA1C levels (OR 2.380; 
95% CI, 0.996–5.688; P . 0.05).
In the case-control study, plasma TNF-α was consistently 
the most important risk factor for PDN, both directly and 
indirectly, by increasing macrophage expression of TNF-α 
and iNOS.
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Figure 1 scatter plots illustrating plasma TnF-α levels, inOs and TnF-α expression in 
patients with Painless Dn (n = 51 ), mild PDn (n = 34) and severe PDn (n = 25).  The short 
horizontal line marks median values. (A) Patients with severe PDn had higher plasma 
TnF-α levels than patients with mild PDn (P , 0.001) and Painless Dn (P , 0.001) 
(B) Patients with severe PDn had higher inOs expression than patients with mild PDn 
(P , 0.001) and Painless Dn (P , 0.001).  (C) Patients with severe PDn had higher plasma 
TnF-α levels than patients with mild PDn (P , 0.001) and Painless Dn (P , 0.001). in 
patients with PDn plasma TnF-α levels were 1.4 (P , 0.05), inOs expression was 2.1 
(P , 0.05), and TnF-α expression were 1.98 (P , 0.05) fold higher than in Painless Dn. 
Abbreviations: PDn, painful diabetic neuropathy; TnF-α, tumor necrosis factor alpha; 
hbA1c, glycosylated hemoglobin; inOs, inducible nitric oxide synthase; pp, post prandial.
Correlation between pain intensity and risk factors for 
PDN (age, duration of diabetes, blood sugar level, HbA1C, 
plasma TNF-α level, TNF-α, and iNOS expression) are 
given in Table 3.
Correlation between pain intensity and age, dura-
tion of diabetes, fasting blood sugar, blood sugar 2 hours 
postprandial, and HbA1C were not statistically significant 
(P . 0.05) whereas correlation between pain intensity 
and plasma TNF-α level, TNF-α, and iNOS expression 
were   statistically   significant (r = 0.330, 0.284, and 0.275, 
respectively; P , 0.05). To investigate the correlation 
Table 3 correlation between pain intensity and some risk factors 
of painful diabetic neuropathy
Variable Pain intensity
R P
Age −0.144 0.275
Duration of diabetes −0.101 0.448
Fasting blood sugar 0.196 0.136
Blood sugar 2 hours post prandial 0.177 0.180
hbA1c 0.138 0.298
Plasma TnF-α 0.330 0.011a
inOs expression 0.284 0.029a
TnF-α expression 0.275 0.035a
Note: aStatistically significant.
Abbreviations:  TnF-α,  tumor  necrosis  factor  alpha;  hbA1c,  glycosylated 
hemoglobin; inOs, inducible nitric oxide synthase.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Discussion
In this study of 110 subjects who fulfilled cross-sectional 
inclusion criteria, all subjects also fulfilled inclusion criteria 
for the case–control study; 59 subjects suffered from PDN 
and 51 subjects suffered from painless DN. All patients who 
had had diabetes for 2 years or more suffered from DN, a 
finding supported by previous work that showed that DN as 
a complication of diabetes was already present in the early 
stage of hyperglycemia before clinical diagnosis.13
Plasma TNF-α and expression of iNOS and TNF-α in 
macrophages according to pain intensity are compared in 
Figure 1. The higher the plasma TNF-α levels, and the iNOS 
and TNF-α expression in macrophages, the more severe the 
pain. These differences were statistically significant. These 
results are in agreement with those of a previous study of 
cytokine expression in nervus suralis biopsy specimen of 
neuropathy patients. Patients with painful neuropathies 
showed a stronger TNF-α immunoreactivity than patients 
with nonpainful neuropathy.14 Another study reported that 
patients with a painful neuropathy had about 2-fold higher 
TNF-α mRNA and protein levels than healthy control sub-
jects, and about 2-fold higher IL-2 and TNF mRNA and 
protein levels than patients with painless neuropathy (all 
differences significant).15
Our study showed plasma TNF-α level in PDN was 
almost 1.5 × higher than PDN, and TNF-α expression in 
PDN was nearly 2 × higher than PDN. Doganay et al inves-
tigated the relationship between the stages of DR (diabetic 
  retinopathy) and serum levels of NO and many inflammatory 
cytokine such as NO, sIL-2R, IL-1β, IL-6, IL-8, and TNF-α. 
Serum NO levels ranged from 80 to 188 µmol/l, with the 
highest values obtained in patients with PDR (proliferative 
diabetic retinopathy). The mean serum NO, sIL-2R, IL-8, and 
TNF-α levels increased with the stage of DR and the highest 
levels were found in patients with PDR16. Patients with small 
fiber neuropathy (SFN) had a 2-fold higher gene expression 
for IL-2 (P , 0.0001), IL-10 (P = 0.01), and transforming 
growth factor-β1 (P = 0.001) in peripheral blood whereas 
patients with length-dependent SFN had higher gene expres-
sion in the affected distal skin than in nonaffected skin for 
TNF-α (2.6-fold; P = 0.04), IL-1β (2-fold; P = 0.02), IL-6 
(.200-fold; P = 0.01), and IL-8 (.500-fold; P = 0.046).17
In our study, the highest levels of plasma TNF-α, and iNOS 
and TNF-α expression, were also found in patients with PDN. 
Pro-inflammatory cytokines (IL-1β, IL-2, IL-6, IFN-γ, TNF-α) 
in the plasma were correlated with increasing pain intensity. 
Chronic pain patients show a significant increase in plasma lev-
els of NO in comparison with healthy controls.4 Another study 
also showed a correlation between pro-  inflammatory cytokine 
and pain intensity or severity of the disease in juvenile rheu-
matoid arthritis18 and fibromyalgia.19
There were positive correlations between pain intensity 
and plasma TNF-α level, and iNOS and TNF-α expression, 
and also a moderate to strong correlation between these 
three risk factors. Correlation between pain intensity and 
age, duration of diabetes, fasting blood sugar, blood sugar 
2 hours postprandial and HbA1C were not statistically sig-
nificant, indicating that above factors were not proven to 
increase PDN.
According to these results and those of some other inves-
tigations, a pathophysiological relationship can be shown 
between TNF-α, iNOS, and PDN, as depicted in Figure 2.
Prolonged hyperglycemia in diabetic patients can cause 
diabetic pain through many mechanisms, including meta-
bolic, oxidative stress, immunologic, advanced glycosylation 
of end products, and vascular. All of these mechanisms are 
closely related to decreased endothelial NOS (eNOS), which 
is followed by a decrease in NO. NO derived from the eNOS 
could inhibit platelet aggregation and proliferation of smooth 
muscle. NO also a potent vasodilator.20 A decrease in NO will 
result in vessel endothelium disruption followed with nerve 
fiber disruption. Under chronic hyperglycemia, endogenous 
TNF-α production is accelerated in microvascular and neural 
tissues, which may undergo increased microvascular perme-
ability, hypercoagulability, and nerve damage, thus initiating 
and promoting the development of DN.21
Dysfunction or lesion in peripheral nerve fibers leads 
to membrane remodeling and hyperexcitability which in 
turn cause diabetic pain. Lesion in primary afferent nerve 
fibers will induce activation of immune resident cells and 
recruitment of inflammatory cells to the inflamed cell. Then 
inflammation cascade takes place as activated mast cells 
release TNF-α which sensitizes nociceptors and contribute 
to neutrophils and macrophages recruitment. In nerve cells, 
neutrophils and macrophages produce and secrete neurotrans-
mitter, neuropeptide and inflammatory mediators such as 
TNF-α, PGE2, bradykinin, serotonin, histamine, and NGF. 
These mixed mediators activate nociceptors directly, cause 
sensitization, and contribute to neuropathic pain, which result 
in pain, spontaneous or primary hyperalgesia.6
Binding of TNF-α to its receptors on the cell surface 
initiates several signalling events, such as activation of p38 
MAP kinase signaling8 and translocation of NFκB into the 
nucleus.9 NFκB then upregulates transcription of several 
genes, including COX-2, iNOS, TNF-α, IL-1β, and IL-6.22 
NFκB itself can be activated by oxygen radicals, suggesting Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Purwata
a positive feedback loop in which NO might activate tran-
scription factors, which in turn could increase NO synthesis 
by causing additional iNOS expression.
The role of NO is thought to be through increased iNOS 
following chronic inflammation in diabetic pain. Strong evi-
dence supports a reciprocal relationship between NO and PGs 
biosynthetic pathways.23 The interaction between NO and PGs 
biosynthesis occurs in some levels. NO directly influences 
COX expression and PGs biosynthesis. Conversely, arachi-
donic acid and its metabolites, which are produced by COX 
isoform, also have an effect on NO biosynthesis. The ability 
of NO to directly activate COX-2 is supported by evidence 
that NO increases purified COX-2 recombinant enzymes. NO 
also influences COX-2 enzyme activities by post-transcription 
and translation processes which make macrophages increase 
their PGs production. There is evidence that NO also activates 
COX-2.24 NO release by constitutive NOS in basal conditions 
deactivates iNOS by inhibition of NFκB signal. NFκB signal 
is one of the signaling pathways for iNOS expression by means 
of extracellular mediators, including TNF-α (proinflammatory 
cytokine) and endotoxin.16 At low NO concentration, NFκB 
remains inactive,23 while at high NO concentration, NFκB is 
not suppressed by NO, so that it activates iNOS by produc-
ing combination anion superoxide from peroxynitrite. NFκB 
is a strong COX-2 inducer and the inhibitory role of NO in 
COX-2 is mediated by NFκB inhibition. NO is produced by 
many types of cells in peripheral tissues after inflammation 
has occurred. Once expressed, iNOS produces NO in large 
amounts for a long period.25
High NO is related to PDN while iNOS inhibitor can 
decrease PDN symptoms.12,26,27 Evidence that TNF-α and 
iNOS have important roles in the pathogenesis of PDN can 
lead to a new strategy of therapy – that of modulating the 
NO pathway and neuroimmune system. Modulation can be 
achieved by specifically inhibiting iNOS, antibody cytokine 
receptors, and TNF-α.
Conclusion
DN patients with high TNF-α levels, and high iNOS and 
TNF-α immunoreactivity of macrophages, are at risk of 
suffering from pain. The higher the TNF-α level, and iNOS 
and TNF-α immunoreactivity, the more severe the pain. 
This supports the hypothesis that TNF-α and iNOS have a 
role in PDN pathogenesis. The results of this research could 
be used as a basis for further research in pursuit of better 
management of PDN.
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